Business
NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma
- NRx Pharmaceuticals (Nasdaq:NRXP) to collaborate with Ministries of Health of Georgia, Hungary, and Ukraine to conduct phase III development of ZYESAM™ in
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"- NRx Pharmaceuticals (Nasdaq:NRXP) to collaborate with Ministries of Health of Georgia, Hungary, and Ukraine to conduct phase III development of ZYESAM™ in coordination with the Senator Richard Lugar Research Institute\n - Costs of approximately $60 million to be shared by NRx and Denk Pharma, Georgia. Cromos Pharma and Denk Pharma will jointly oversee clinical development and distribution\n - NRx dedicated to development of innovative medicines and vaccines for life-threatening, unmet medical needs in its mission of \"Bringing Hope to Life\"\n - NRx expects to receive Emergency Use Authorization for ZYESAMI™ (Aviptadil acetate) to treat critically-ill patients suffering respiratory failure in Covid-19 in the face of current pandemic conditions\n\n\nRADNOR, Pa., May 26, 2021 /PRNewswire/ -- Today, NRx Pharmaceuticals, Inc., (Nasdaq:NRXP) (NRx) through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview, Washington, to conduct phase 3 clinical trials of COVID-19 related drugs and vaccines in Central Europe and the Caucasus Region. The Senator Richard Lugar Research Institute, a US Government-funded regional research laboratory also serves as part of the collaboration. This region comprises a population of more than 500 million people, many of whom lack access to current COVID-19 vaccines and therapies. \n\n \n \n \n \n \n \n\n \nNRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region \"As a newly-listed Nasdaq company we are set to deliver on our plans to deliver lifesaving medicines and vaccines where none exist and fulfill our credo of \"Bringing Hope to Life,\" said Prof. Jonathan Javitt, MD, MPH, CEO and, Chairman of the Board of NRx. \"We are honored by the trust bestowed upon us by the governments and people of this region. We aim to complete our inhaled drug trial by September 2021 and to seek emergency use authorization for inhaled ZYESAMI™ from regional regulators.\nNRx CEO and Chairman, Jonathan Javitt, MD, MPH met this month with the Prime Minister and Health Minister of Georgia and, with senior officials from the Ministry of Health of Ukraine to confirm final plans for the June 2, 2021 study initiation.\nNRx's collaborative efforts for this initiative are led by NRx senior leade...